Erlotinib for Treatment of Psoriasis

Recruiting in Palo Alto (17 mi)

Overseen by Anne E Laumann, MBChB, MRCP (UK)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Northwestern University

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

The purpose of this study is to determine whether erlotinib is effective in the treatment of psoriasis.

Research Team

Anne E Laumann, MBChB, MRCP (UK)

Principal Investigator

Northwestern University

Eligibility Criteria

Inclusion Criteria

Clinical diagnosis of moderate to severe psoriasis

Must have documented moderate to severe psoriasis by the Physician's Global Assessment (PGA) and the Psoriasis Area Severity Index (PASI)

Must be able to swallow tablets

Treatment Details

Interventions

• Erlotinib (Tyrosine Kinase Inhibitor)

Participant Groups

Group I: Erlotinib Experimental Treatment 1 Intervention

Group II: Placebo tablets Placebo Group 1 Intervention

Erlotinib is already approved in Canada for the following indications:

Approved in Canada as Tarceva for:

• Non-small cell lung cancer
• Pancreatic cancer

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

Northwestern University Feinberg School of Medicine Department of Dermatology Chicago, IL

Who Is Running the Clinical Trial?

Northwestern University

Lead Sponsor

Trials

1674

Patients Recruited

989,000+

OSI Pharmaceuticals

Industry Sponsor

Trials

73

Patients Recruited

6,000+